Ads
related to: abbvie share price
Search results
Results From The WOW.Com Content Network
The dividend is rock-solid and should continue growing along with the share price over the coming years. That makes AbbVie a solid buy today. Should you invest $1,000 in AbbVie right now?
With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to ...
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois.It is ranked sixth on the list of largest biomedical companies by revenue.In 2023, the company's seat in Forbes Global 2000 was 74, [2] and rank 89 on the 2024 list. [3]
AbbVie also pays a rather generous 3.63% yield at current levels, a figure that towers over the 1.35% average yield of the benchmark S&P 500 index. The one cautionary note is that AbbVie's payout ...
ABBV Total Return Level data by YCharts.. The lesson: AbbVie's business is strong. The company's dividend program makes the stock that much more attractive and capable of delivering superior ...
AbbVie's shares currently trade at 14.2 times 2026 projected earnings, a modest discount to the blue-chip biotech peer average of around 15 times 2026 forward earnings.
The company's adjusted earnings per share increased by 1.7% year over year to $3. AbbVie's portfolio of drugs, especially Humira's heirs in immunology, Skyrizi and Rinvoq, are picking up the slack ...
AbbVie is also facing pressure on its big-selling cancer drug Imbruvica, which was selected as one of the 10 medicines subject to the first-ever price negotiations by U.S. Medicare insurance plans.